Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Hydronidone Capsules in Healthy Chinese Volunteers
NCT04125056Phase 1Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hydronidone in Liver Fibrosis (LF) (2 arms), sponsored by Gyre Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration up to 12 weeks, Area Under the Curve up to 12 weeks and 1 more. Started Jan 2019; status: completed.
02
Drugs
hydronidone
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT04125056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04125056.